Pulmatrix, Inc.
PULMPulmatrix, Inc. in brief
Pulmatrix, Inc. is a listed company in the Biotechnology industry, based in Framingham, Massachusetts, USA. Its market value was $6 M on 1 August 2026, which makes it the 26,621st largest listed company in the world and the 4,372nd largest in the USA on this site. Its shares trade under the symbol PULM (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Pulmatrix, Inc.
We are a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using our patented iSPERSE™ technology. Our proprietary product pipeline includes treatments for central nervous system disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease and allergic bronchopulmonary aspergillosis. Our product candidates are based on our proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes.
From the company's annual report filed with the US SEC: read the report
Pulmatrix, Inc. timeline
- 2013
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- 🔔· approximateInitial public offering on Nasdaq
- 2015
- ✎Renamed Pulmatrix, Inc.Formerly Ruthigen, Inc..
- 2020
- 💰Record revenue of $13 millionFY2020, the highest of the 7 years on record.
Events of Pulmatrix, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,314 (Jan 2020) · #4,154 (Jan 2021) · #5,334 (Jan 2022) · #5,472 (Dec 2022) · #4,557 (Jan 2024) · #2,417 (Mar 2026) · #4,099 (Aug 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.6×
- Free cash flow yield
- -185.3%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -135.4%
- Liabilities / assets
- 8.0%
- Net debt
- $-1M
- Revenue growth
- +7.0%
- R&D / revenue
- 91.8%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-5M | $-5M | — |
| Dec 2024 | $8M | +7.0% | $-10M | $-10M | -122.4% |
| Dec 2023 | $7M | +20.3% | $-15M | $-14M | -193.4% |
| Dec 2022 | $6M | +17.4% | $-19M | $-19M | -310.4% |
| Dec 2021 | $5M | -59.1% | $-20M | $-20M | -390.1% |
| Dec 2020 | $13M | +59.7% | $-10M | $-19M | -152.9% |
| Dec 2019 | $8M | +5173.3% | $-21M | $-21M | -260.4% |
| Dec 2018 | $0M | — | $-20M | $-21M | -13706.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-5M | — | — | $-1.41 | — |
| Dec 2024 | $-11M | $0M | $-11M | $-2.62 | — |
| Dec 2023 | $-16M | $1M | $-17M | $-3.87 | — |
| Dec 2022 | $-19M | $0M | $-19M | $-5.46 | — |
| Dec 2021 | $-20M | $0M | $-20M | $-8.63 | — |
| Dec 2020 | $-12M | $0M | $-13M | $-13.43 | — |
| Dec 2019 | $3M | $0M | $3M | $-1.23 | — |
| Dec 2018 | $-17M | $0M | $-17M | $-4.98 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 27, 20268-KCurrent reportShareholder vote
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jun 16, 202610-K/AAnnual report (amended) · period to Dec 2025
- May 15, 202610-QQuarterly report · period to Mar 2026
- May 15, 20268-KCurrent reportResults of operations
- Apr 21, 20268-KCurrent reportRegulation FD disclosure · Other events
- Mar 27, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Change in control · Bylaws amended · Regulation FD disclosure
- Mar 2, 20268-KCurrent reportAgreement ended · Regulation FD disclosure
- Feb 26, 20268-KCurrent reportResults of operations
- Feb 26, 202610-KAnnual report · period to Dec 2025
- Dec 18, 20258-KCurrent reportRegulation FD disclosure · Other events
Official filings of Pulmatrix, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-5 M
- Net income
- $-5 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $4 M
- Total liabilities
- $0 M
- Total equity
- $4 M
As of December-2025
Top 16 institutional investors in Pulmatrix, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies LLC | 120,220 | -2,478 (-2.02%) | 3.29% | $0 M | Nov 12, 2026 |
| 2 | BlackRock, Inc. | 54,899 | 0 (0.00%) | 1.50% | $0 M | Nov 13, 2026 |
| 3 | Shay Capital LLC | 33,958 | +15,101 (+80.08%) | 0.93% | $0 M | Nov 16, 2026 |
| 4 | Geode Capital Management, LLC | 33,202 | -97 (-0.29%) | 0.91% | $0 M | Nov 6, 2026 |
| 5 | Vanguard Capital Management LLC | 32,294 | 0 (0.00%) | 0.88% | $0 M | Nov 13, 2026 |
| 6 | SBI Securities Co., Ltd. | 30,165 | -1,120 (-3.58%) | 0.83% | $0 M | Oct 22, 2026 |
| 7 | Vanguard Fiduciary Trust Co | 14,715 | 0 (0.00%) | 0.40% | $0 M | Nov 13, 2026 |
| 8 | Susquehanna International Group, LLP | 14,252 | New | 0.39% | $0 M | Nov 16, 2026 |
| 9 | State Street Corp | 13,945 | 0 (0.00%) | 0.38% | $0 M | Nov 12, 2026 |
| 10 | Virtu Financial LLC | 13,722 | New | 0.38% | $0 M | Nov 17, 2026 |
| 11 | UBS Group AG | 10 | -505 (-98.06%) | 0.00% | $0 M | Nov 10, 2026 |
| 12 | Royal Bank Of Canada | 7 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 13 | Farther Finance Advisors, LLC | 7 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 14 | Barclays PLC | 4 | -11 (-73.33%) | 0.00% | $0 M | Nov 6, 2026 |
| 15 | Allworth Financial LP | 3 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 16 | Northwestern Mutual Wealth Management Co | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding Pulmatrix, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 32,294 | $0 M | 0.88% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 23,014 | $0 M | 0.63% | <0.01% | +18% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 5,228 | $0 M | 0.14% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 4,570 | $0 M | 0.13% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 4,427 | $0 M | 0.12% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 5 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Pulmatrix, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Mark T. IwickiDirector | Buy | +307,000 | — | — | 307,000 | Form 4 |
| filed | ARCH Venture Partners VII, L.P.Former 10% owner | Buyindirect | +1.15 M | — | — | 3.44 M | Form 4 |
| filed | Matthew L. ShermanDirector | Buy | +20,000 | — | — | 20,000 | Form 4 |
| filed | Polaris Venture Management Co. V, L.L.C.10% owner | Buyindirect | +345,551 | — | — | 1.56 M | Form 4 |
| filed | Polaris Venture Management Co. V, L.L.C.10% owner | Buyindirect | +6,478 | — | — | 29,178 | Form 4 |
| filed | Polaris Venture Management Co. V, L.L.C.10% owner | Buyindirect | +769,989 | — | — | 3.47 M | Form 4 |
| filed | Polaris Venture Management Co. V, L.L.C.10% owner | Buyindirect | +15,007 | — | — | 67,729 | Form 4 |
| filed | Polaris Venture Management Co. V, L.L.C.10% owner | Buyindirect | +5,275 | — | — | 23,875 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Pulmatrix, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-2.5 reverse split
Trading halts
- 2026-03-26 11:59 UTC, code T3, resumed 12:30 UTC
- 2025-12-19 14:30 UTC, code LUDP, resumed 14:35 UTC
- 2025-06-25 15:11 UTC, code LUDP, resumed 15:16 UTC
- 2025-06-23 16:15 UTC, code LUDP, resumed 16:20 UTC
- 2025-06-23 16:08 UTC, code LUDP, resumed 16:13 UTC
Fails to deliver
- : 276 shares at $1.66
- : 18 shares at $1.72
- : 844 shares at $1.88
- : 87 shares at $1.70
- : 1,576 shares at $1.63
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Pulmatrix, Inc. scorecard#
Passes 3 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.41 vs -2.62Diluted EPS -1.41 in fiscal 2025 against -2.62 the year before (report's currency).
- ✓Net income higher than five years earlier-$5 M-$5 M in fiscal 2025 against -$19 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$5 MNet income -$5 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-80.9%-80.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities12.5×Current ratio 12.52 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year0.0%Diluted shares down 0.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Pulmatrix, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | 7.8+7.0%100% | 7.3+20.2%100% | 6.1+17.5%100% | 5.2−59.1%100% | 13+59.7%100% | 7.9+5070%100% | 0.2−54.3%100% | 0.3−59.9%100% | 0.8—100% | |
| Research and development | 0.0−99.5%— | 7.2−53.8%91.8% | 16−14.9%213% | 18+18.6%300% | 15−1.5%298% | 16+21.5%124% | 13−0.9%162% | 13+26.6%8475% | 10+0.9%3058% | 10—1216% | |
| General and administrative | 5.1−34.1%— | 7.8+19.4%99.7% | 6.5−3.8%89.3% | 6.8+6.3%112% | 6.4−7.4%123% | 6.9−18.9%54.5% | 8.5+12.9%107% | 7.5−0.6%4914% | 7.6−5.6%2259% | 8.0—960% | |
| Operating expenses | 5.2−70.6%— | 18−20.3%225% | 22−11.9%302% | 25−1.3%412% | 25+12.6%490% | 22−21.3%178% | 29+39.2%362% | 21r20+15.4%13433% | 18−30.7%5316% | 26—3078% | |
| Operating income | −5.2—— | −9.8—−125% | −15—−202% | −19—−312% | −20—−390% | −9.9—−78.1% | −21—−262% | −20r−20—−13333% | −17—−5216% | −25—−2978% | |
| Interest and finance income | 0.1−69.2%— | 0.5—6.0% | — | — | — | 0.1−72.8%0.6% | 0.3+1015%3.8% | 0.0—17.6% | — | — | |
| Interest expense and finance costs | — | — | — | — | — | — | — | 0.2−71.1%122% | 0.6−27.0%192% | 0.9—106% | |
| Net interest income | — | 0.5−46.1%6.0% | 0.9+181%11.9% | 0.3+4314%5.1% | 0.0−91.5%0.1% | 0.1—0.6% | — | — | — | — | |
| Other non-operating income (expense) | 0.0−96.6%— | 0.2−67.0%2.6% | 0.6+458%8.5% | 0.1—1.8% | −0.0—−0.1% | −9.4−9940%−74.8% | 0.1—1.2% | −0.2r−0.2—−107% | −0.6r0.0—−173% | −0.0—−0.2% | |
| Income before tax | — | — | — | — | — | — | — | — | −18—−5390% | −31—−3689% | |
| Income tax | 0—— | — | — | — | — | — | — | — | — | −3.0—−354% | |
| Net income including minority interests | — | — | — | — | — | — | −21—−260% | −21—−13440% | −18—−5390% | — | |
| Net income attributable to shareholders | −5.2—— | −9.6—−122% | −14—−193% | −19—−310% | −20—−390% | −19—−153% | −21—−260% | −21—−13440% | −18—−5390% | −28—−3334% | |
| Earnings per share, basic | -1.41—— | -2.62—— | -3.87—— | -5.46—— | -8.63—— | -13.43r-0.67—— | -1.23—— | -4.98—— | -9.32r-0.93—— | -1.88—— | |
| Earnings per share, diluted | -1.41—— | -2.62—— | -3.87—— | -5.46—— | -8.63—— | -13.43r-0.67—— | -1.23—— | -4.98—— | -9.32r-0.93—— | -1.88—— | |
| Shares, weighted average (basic) | 3.70.0%— | 3.7+0.0%— | 3.7r3,652−99.9%— | 3,448r3.4+127189%— | 2.7—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 3.70.0%— | 3.7+0.0%— | 3.7r3,652−99.9%— | 3,448+127189%— | 2.7+88.4%— | 1.4r29−91.4%— | 17+306%— | 4.1+113%— | 1.9r19−86.9%— | 15—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 4.1−57.1%98.8% | 9.5−50.3%95.8% | 19−46.2%56.5% | 36−33.8%87.0% | 54+70.1%91.5% | 32+35.1%83.1% | 23+815%64.9% | 2.6−27.8%17.4% | 3.6−15.1%22.2% | 4.2—25.1% | |
| Receivables | — | — | 0.9−28.5%2.7% | 1.3+1837%3.2% | 0.1−20.2%0.1% | 0.1−98.8%0.2% | 7.2—19.9% | — | — | — | |
| Other current assets | 0.0−89.7%1.0% | 0.4−46.2%4.0% | 0.7−30.5%2.2% | 1.1+22.6%2.6% | 0.9+20.5%1.5% | 0.7r0.8−6.9%1.9% | 0.8+8.4%2.2% | 0.7+3.0%4.9% | 0.7+20.6%4.4% | 0.6—3.5% | |
| Current assets | 4.1−58.4%99.8% | 9.9−52.4%99.8% | 21−45.4%61.4% | 38−30.4%93.1% | 55+68.7%93.1% | 32r33+3.3%85.2% | 31+858%87.0% | 3.3−22.8%22.3% | 4.2−10.8%26.6% | 4.8—28.6% | |
| Property, plant and equipment | — | — | 1.2+393%3.4% | 0.2−26.8%0.6% | 0.3−11.1%0.5% | 0.4+33.7%0.9% | 0.3−31.5%0.7% | 0.4−35.8%2.7% | 0.6−21.9%3.8% | 0.8—4.7% | |
| Right-of-use (leased) assets | — | — | 10+1352%30.4% | 0.7−66.1%1.7% | 2.1+40.6%3.6% | 1.5+136%3.9% | 0.6—1.7% | — | — | — | |
| Goodwill | — | — | — | — | — | 3.60.0%9.4% | 3.6−67.0%9.9% | 11−0.6%73.7% | 110.0%68.3% | 11—65.5% | |
| Total assets | 4.1−58.4%100% | 9.9−70.7%100% | 34−17.1%100% | 41−30.4%100% | 59+54.4%100% | 38r38+5.5%100% | 36+145%100% | 15−7.9%100% | 16−4.1%100% | 17—100% | |
| Accounts payable | 0.3−66.4%6.6% | 0.8−57.8%8.1% | 1.9+61.2%5.6% | 1.2+41.6%2.9% | 0.8−1.4%1.4% | 0.9r0.9+41.8%2.2% | 0.6−49.3%1.7% | 1.2+159%8.0% | 0.5−38.8%2.9% | 0.7—4.5% | |
| Debt due within a year | — | — | — | — | — | — | — | 0−100%0.0% | 3.2+24.6%20.2% | 2.6—15.5% | |
| Current liabilities | 0.3−64.6%7.9% | 0.9−76.2%9.3% | 3.9−22.2%11.5% | 5.0+13.1%12.3% | 4.4−45.7%7.6% | 8.2r8.3−52.4%21.5% | 17+497%47.6% | 2.9−50.7%19.6% | 5.8r5.8+25.6%36.6% | 4.7—27.9% | |
| Long-term debt | — | — | — | — | — | — | — | — | — | 3.2—19.3% | |
| Lease liabilities (non-current) | — | — | 8.3—24.5% | — | 0.9+41.0%1.5% | 0.6—1.6% | — | — | — | — | |
| Total liabilities | 0.3−67.0%7.9% | 1.0−93.8%10.0% | 16+62.2%47.0% | 9.8−13.4%24.0% | 11−24.0%19.3% | 15r15−40.4%39.3% | 25+771%69.5% | 2.9−50.7%19.6% | 5.8−26.1%36.6% | 7.9—47.4% | |
| Retained earnings | −302—−7304% | −297—−2989% | −288—−847% | −273—−668% | −255—−433% | −234—−615% | −215—−596% | −195—−1322% | −174—−1089% | −156—−936% | |
| Shareholders' equity | 3.8−57.4%92.1% | 8.9−50.3%90.0% | 18−42.2%53.0% | 31−34.4%76.0% | 47+105%80.7% | 23+110%60.7% | 11−7.0%30.5% | 12+16.8%80.4% | 10+15.7%63.4% | 8.8—52.6% | |
| Total liabilities and equity | 4.1−58.4%100% | 9.9−70.7%100% | 34−17.1%100% | 41−30.4%100% | 59+54.4%100% | 38r38+5.5%100% | 36+145%100% | 15−7.9%100% | 16−4.1%100% | 17—100% | |
| Shares outstanding | 3.70.0%— | 3.70.0%— | 3.7+0.4%— | 3.6+12.9%— | 3.2+78.5%— | 1.8r36−91.0%— | 20+306%— | 4.9r4.9+134%— | 2.1r21−85.8%— | 15—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | 0.1−20.9%1.4% | 0.1−17.3%1.8% | 0.2−4.1%2.7% | 0.2−21.4%3.3% | 0.2+18.1%1.7% | 0.2−21.2%2.3% | 0.2−6.1%151% | 0.2−1.6%73.4% | 0.3—29.9% | |
| Share-based compensation | 0.0−95.1%— | 0.5−46.4%6.5% | 1.0−14.4%13.1% | 1.1−3.8%18.3% | 1.20.0%22.4% | 1.2−43.9%9.2% | 2.1−30.5%26.1% | 3.0+5.5%1943% | 2.8−29.5%841% | 4.0—479% | |
| Cash from operating activities | −5.4—— | −11—−137% | −16—−219% | −19—−319% | −20—−382% | −12−486%−98.8% | 3.2—40.8% | −17—−10955% | −14—−4321% | −13—−1586% | |
| Capital expenditure | — | −0.4—−5.1% | −0.7—−9.3% | −0.1—−1.4% | −0.1—−2.8% | −0.3—−2.2% | −0.1—−0.7% | −0.0—−12.4% | −0.1—−22.1% | −0.5—−54.5% | |
| Cash from investing activities | — | −0.4—−5.1% | −0.7—−9.3% | −0.1—−1.4% | −0.1—−2.8% | −0.3—−2.2% | −0.1—−0.7% | −0.0—−12.4% | −0.1—−22.1% | −0.4—−51.6% | |
| Debt issued | — | — | — | — | — | 0.6—4.9% | — | — | — | — | |
| Debt repaid | — | — | — | — | — | −0.6—−4.9% | — | — | — | — | |
| Shares issued | — | — | 0.1−96.2%0.7% | 1.4−96.3%22.8% | 37+407%717% | 7.3−58.3%57.9% | 18+374%222% | 3.7—2418% | — | — | |
| Cash from financing activities | — | — | 0.1−95.7%0.7% | 1.2−97.2%20.3% | 43+107%841% | 21+18.5%166% | 18+12.1%224% | 16+13.5%10322% | 14—4155% | −1.0—−125% | |
| Change in cash | −5.4—— | −11—−142% | −17—−228% | −18−177%−300% | 24+187%457% | 8.2−60.6%65.0% | 21—264% | −1.0—−645% | −0.6—−189% | −15—−1763% | |
| Report | 10-K/A | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | — | 0.0*−99.9%100% | 0.4−79.1%100% | 1.6—100% | 5.9—100% | 2.2*—100% | 1.8—100% | |
| Research and development | — | 0.0−85.7%— | 0.0−84.2%— | — | 0.0−99.0%— | 0.0−99.5%— | 0.0−99.5%— | 0.0*−99.8%200% | 0.8−79.5%222% | 2.8—183% | 3.5—59.7% | 3.5*—160% | 4.0—226% | |
| General and administrative | 4.1−45.5%— | 1.0−31.9%— | 1.3−29.5%— | 0.9*−53.3%— | 0.9−61.2%— | 1.5−23.3%— | 1.8+12.4%— | 1.9*+114%64967% | 2.2+27.8%604% | 2.0—129% | 1.6—27.6% | 0.9*—41.4% | 1.7—98.6% | |
| Operating expenses | 4.1−50.9%— | 1.0−32.4%— | 1.3−30.0%— | 0.9*−53.6%— | 0.9−71.4%— | 1.5−79.2%— | 1.8−64.1%— | 2.0*−55.8%65167% | 3.0−46.9%826% | 7.5—480% | 5.1—87.3% | 4.4*—201% | 5.7—325% | |
| Operating income | −4.1—— | −1.0—— | −1.3—— | −0.9*—— | −0.9—— | −1.5—— | −1.8−347%— | −2.0*—−65067% | −2.7—−726% | −5.9—−380% | 0.7—12.7% | −2.2*—−101% | −3.9—−225% | |
| Interest and finance income | 0.1−73.1%— | 0.0−75.6%— | 0.0−77.4%— | 0.0*−72.6%— | 0.0−70.3%— | 0.0−69.2%— | 0.1—— | 0.1*—2433% | 0.1—27.6% | 0.1—8.6% | — | — | — | |
| Net interest income | — | — | — | — | — | — | 0.1−66.9%— | 0.1*−62.0%2433% | 0.1−53.5%27.6% | 0.1—8.6% | 0.2—2.7% | 0.2*—8.7% | 0.2—12.4% | |
| Other non-operating income (expense) | 0.1+33.8%— | 0.0—— | 0.1+208%— | −0.0*—— | −0.0−116%— | −0.0−101%— | 0.0−50.0%— | −0.0*−124%−1133% | 0.1−57.6%19.1% | 0.1—5.8% | 0.1—1.3% | 0.1*—6.4% | 0.2—9.4% | |
| Income tax | — | — | — | 0*—— | 0—— | 0—— | 0—— | — | 0—0.0% | 0—0.0% | 0—0.0% | — | 0—0.0% | |
| Net income attributable to shareholders | −4.0—— | −1.0—— | −1.2—— | −0.9*—— | −0.9—— | −1.5—— | −1.8−319%— | −2.0*—−66200% | −2.6—−707% | −5.8—−374% | 0.8—14.0% | −2.1*—−94.6% | −3.8—−215% | |
| Earnings per share, basic | — | -0.29—— | -0.32—— | — | -0.24—— | -0.42—— | -0.50r0.50−317%— | — | -0.71—— | -1.59—— | 0.23—— | — | -1.03—— | |
| Earnings per share, diluted | — | -0.29—— | -0.32—— | — | -0.24—— | -0.42—— | -0.50r0.50−317%— | — | -0.71—— | -1.59—— | 0.23—— | — | -1.03—— | |
| Shares, weighted average (basic) | 3.70.0%— | 3.70.0%— | 3.70.0%— | — | 3.70.0%— | 3.70.0%— | 3.70.0%— | — | 3.70.0%— | 3.7—— | 3.7—— | — | 3.7r3,652—— | |
| Shares, weighted average (diluted) | 3.70.0%— | 3.70.0%— | 3.70.0%— | — | 3.70.0%— | 3.70.0%— | 3.70.0%— | — | 3.70.0%— | 3.7—— | 3.7—— | — | 3.7r3,652—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 2.2—66.8% | 2.2−62.8%66.8% | 3.3−56.9%73.9% | 4.1−57.1%98.8% | 4.8−55.5%96.2% | 5.8−52.9%94.7% | 7.7−52.7%95.7% | 9.5−50.3%95.8% | 11−49.5%93.7% | 12—78.4% | 16—53.6% | 19—56.5% | 21—58.0% | |
| Receivables | — | — | — | — | — | — | 0.0−97.2%0.2% | — | 0.0−97.3%0.2% | 0.6—4.0% | 0.6—1.9% | 0.9—2.7% | 0.8—2.3% | |
| Other current assets | 0.4—11.4% | 0.4+17.0%11.4% | 0.5+46.7%10.3% | 0.0−89.7%1.0% | 0.2−72.2%3.6% | 0.3−73.6%5.2% | 0.3−55.5%3.9% | 0.4−46.2%4.0% | 0.6−28.7%5.6% | 1.2—7.6% | 0.7—2.3% | 0.7—2.2% | 0.9—2.4% | |
| Current assets | 3.2—99.8% | 3.2−47.3%99.8% | 4.5−44.2%99.8% | 4.1−58.4%99.8% | 5.0−56.6%99.8% | 6.1−60.7%99.8% | 8.0−54.3%99.9% | 9.9−52.4%99.8% | 11−50.7%99.4% | 16—99.1% | 18—57.9% | 21—61.4% | 23—63.2% | |
| Property, plant and equipment | — | — | — | — | — | — | — | — | — | — | 1.1—3.6% | 1.2—3.4% | 1.2—3.2% | |
| Right-of-use (leased) assets | — | — | — | — | — | — | — | — | — | — | 10—33.2% | 10—30.4% | 11—29.1% | |
| Total assets | 3.2—100% | 3.2−47.2%100% | 4.5−44.2%100% | 4.1−58.4%100% | 5.0−56.7%100% | 6.2−61.0%100% | 8.1−73.5%100% | 9.9−70.7%100% | 12−68.7%100% | 16—100% | 30—100% | 34—100% | 37—100% | |
| Accounts payable | 0.5—16.3% | 0.5+37.8%16.3% | 0.7−0.9%14.5% | 0.3−66.4%6.6% | 0.1−81.5%1.4% | 0.4−2.3%6.2% | 0.7−8.9%8.2% | 0.8−57.8%8.1% | 0.4−47.2%3.2% | 0.4—2.5% | 0.7—2.4% | 1.9—5.6% | 0.7—1.9% | |
| Current liabilities | 0.7—21.2% | 0.7+25.7%21.2% | 0.9+0.2%20.1% | 0.3−64.6%7.9% | 0.2−57.8%5.0% | 0.5−77.8%8.9% | 0.9−71.3%11.2% | 0.9−76.2%9.3% | 0.6−86.7%5.1% | 2.5—15.7% | 3.1—10.3% | 3.9—11.5% | 4.4—12.0% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | — | — | 8.2—27.1% | 8.3—24.5% | 8.4—22.9% | |
| Total liabilities | 0.7—21.2% | 0.7+25.7%21.2% | 0.9+0.1%20.1% | 0.3−67.0%7.9% | 0.2−57.8%5.0% | 0.5−77.8%8.9% | 0.9−92.1%11.2% | 1.0−93.8%10.0% | 0.6−96.5%5.1% | 2.5—15.7% | 11—37.4% | 16—47.0% | 17—45.9% | |
| Retained earnings | −305—−9382% | −305—−9382% | −303—−6750% | −302—−7304% | −301—−6050% | −301—−4885% | −299—−3713% | −297—−2989% | −295—−2564% | −293—−1854% | −287—−944% | −288—−847% | −286—−776% | |
| Shareholders' equity | 2.6—78.8% | 2.6−54.4%78.8% | 3.6−49.8%79.9% | 3.8−57.4%92.1% | 4.7−56.7%95.0% | 5.6−57.9%91.1% | 7.1−62.4%88.8% | 8.9−50.3%90.0% | 11−45.1%94.9% | 13—84.3% | 19—62.6% | 18—53.0% | 20—54.1% | |
| Total liabilities and equity | 3.2—100% | 3.2−47.2%100% | 4.5−44.2%100% | 4.1−58.4%100% | 5.0−56.7%100% | 6.2−61.0%100% | 8.1−73.5%100% | 9.9−70.7%100% | 12−68.7%100% | 16—100% | 30—100% | 34—100% | 37—100% | |
| Shares outstanding | 3.7—— | 3.70.0%— | 3.70.0%— | 3.70.0%— | 3.70.0%— | 3.70.0%— | 3.70.0%— | 3.70.0%— | 3.70.0%— | 3.7—— | 3.7—— | 3.7—— | 3.7—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | 0*−100%0.0% | 0*−100%0.0% | 0.0*—3.0% | 0.1—1.0% | 0.0*—1.7% | 0.0*—1.8% | |
| Share-based compensation | 0.0−92.9%— | 0.0−66.7%— | 0.0−62.5%— | 0.0*−61.5%— | 0.0−97.0%— | 0.0−94.2%— | 0.0−96.0%— | 0.0*−93.4%433% | 0.2−4.4%53.8% | 0.1—6.6% | 0.2—3.4% | 0.2*—8.9% | 0.2—11.8% | |
| Cash from operating activities | −3.9—— | −1.1*—— | −1.1—— | −0.7*—— | −1.0*—— | −1.9*—— | −1.8—— | −1.3*—−42033% | −3.1*—−836% | −3.7*—−237% | −2.7—−46.2% | −2.0*—−91.3% | −4.1*—−236% | |
| Capital expenditure | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | −0.2*—−15.7% | −0.2—−2.6% | −0.3*—−13.9% | −0.3*—−17.9% | |
| Cash from investing activities | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | −0.2*—−15.7% | −0.2—−2.6% | −0.3*—−13.9% | −0.3*—−17.9% | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | |
| Cash from financing activities | — | −0.1*—— | 1.0—— | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | |
| Change in cash | −3.0—— | −1.2*—— | −0.1—— | −0.7*—— | −1.0*—— | −1.9*—— | −1.8—— | −1.3*—−42033% | −3.1*—−836% | −3.9*—−253% | −2.9—−48.8% | −2.3*—−105% | −4.5*—−254% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K/A | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Pulmatrix, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Change in control 3 · Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 4 · Agreement ended 1 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Change in controlMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Agreement ended | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Acquisition or sale completed | 8-K | |
| Change in controlMaterial agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Change in controlDirectors and officersMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 27, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2026 | $1 M | Private placement after listing | Under $2 million | 1 | equity | SEC |
| Apr 2020 | $8 M | Private placement after listing | $2 to $10 million | 3 | options | SEC |
| Feb 2019 | $2 M | Private placement after listing | $2 to $10 million | 7 | options | SEC |
| Dec 2018 | $4 M | Private placement after listing | $2 to $10 million | 1 | options | SEC |
| Jun 2015 | $21 M | Private placement after listing | $10 to $50 million | 12 | equity, options | SEC |
| Jun 2015 | $3 M | Private placement after listing | $2 to $10 million | 34 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Pulmatrix, Inc.#
1 labor condition applications certified in fiscal 2023 for 1 positions, at a median wage of $112 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Engineer I/Scientist IChemists | 1 | $112 K |
Where: Lexington, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2023 | 1 | 1 | $112 K | 1 |
| FY2022 | 2 | 2 | $101 K | 2 |
| FY2020 | 2 | 2 | $96 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Pulmatrix, Inc.
How Pulmatrix, Inc. compares in Biotechnology
- Market cap$6 M · higher than 7% of 726
- Revenue growth7.0% · higher than 50% of 438
- Price / book1.6× · lower than 65% of 534
- FCF yield-185.3% · higher than 2% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Pulmatrix, Inc.🇺🇸 | $6 M | — | — | +7.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Pulmatrix, Inc.? Verify and update this profile — free
Show Pulmatrix, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.